---
document_datetime: 2023-09-21 20:29:21
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/drovelis-epar-all-authorised-presentations_en.pdf
document_name: drovelis-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8308328
conversion_datetime: 2025-12-20 15:49:35.013321
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administration Immediate Packaging Pack size

| EU/1/21/1547/001   | Drovelis   | 3 mg / 14.2 mg   | Film-coated tablet   | Oral use   | blister (PVC/alu)   | 28 tablets   |
|--------------------|------------|------------------|----------------------|------------|---------------------|--------------|
| EU/1/21/1547/002   | Drovelis   | 3 mg / 14.2 mg   | Film-coated tablet   | Oral use   | blister (PVC/alu)   | 84 tablets   |
| EU/1/21/1547/003   | Drovelis   | 3 mg / 14.2 mg   | Film-coated tablet   | Oral use   | blister (PVC/alu)   | 168 tablets  |
| EU/1/21/1547/004   | Drovelis   | 3 mg / 14.2 mg   | Film-coated tablet   | Oral use   | blister (PVC/alu)   | 364 tablets  |